Vaciamiento gástrico y diabetes mellitus tipo 2

Publicado

2015-04-01

Gastric emptying and Type 2 diabetes mellitus

Palabras clave:

Diabetes mellitus Tipo 2, Péptido 1 similar al glucagón, Vaciamiento gástrico, Incretinas (es)
Diabetes mellitus Type 2, Glucagon-like peptide 1, Gastric emptying, Incretins (en)

Descargas

PDF
HTML

Autores/as

Camilo Andrés Quintero-Cadavid Unidad de Endocrinología, Facultad de Medicina, Universidad Nacional de Colombia. Bogotá D. C., Colombia.
William Otero-Regino Unidad de Gastroenterología, Facultad de Medicina, Universidad Nacional de Colombia. Bogotá D. C., Colombia. Clínica Fundadores. Bogotá D. C., Colombia.
Roberto Franco-Vega Unidad de Gastroenterología, Facultad de Medicina, Universidad Nacional de Colombia. Bogotá D. C., Colombia.

Resumen (es)
Resumen (en)

El adecuado control de la diabetes mellitus tiene una gran importancia desde muchos puntos de vista. En los últimos años, se ha destacado el impacto que tienen los niveles de la glucemia postprandial sobre el manejo y las complicaciones de esta enfermedad. Controlar la hiperglucemia postprandial y, por lo tanto, su participación en el deterioro clínico de los pacientes con diabetes puede conseguirse retardando el vaciamiento gástrico y estimulando el efecto incretina, los cuales se pueden promover utilizando los análogos del péptido similar al glucagón tipo 1 (GLP-1). En este artículo se revisa el concepto del efecto incretina y la utilidad de los análogos GLP-1 en el control de la glicemia en los pacientes con diabetes mellitus tipo 2.

Proper control of diabetes mellitus is very important from many points of view. In recent years, the impact of postprandial blood glucose levels on the treatment and complications of this disease has been highlighted. Controlling postprandial hyperglycemia—and, therefore, its participation in the clinical deterioration of patients with diabetes—can be achieved by delaying gastric emptying and stimulating the incretin effect, which can be promoted using the analogues of glucagon-like peptide-1 (GLP-1). In this article, the concept of the incretin effect and usefulness of GLP-1 analogues for glycemic control in patients with type 2 diabetes mellitus is reviewed.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF Diabetes Atlas [Internet]. 6th edition. Brussels, Belgium: International Diabetes Federation; 2013 [cited 2015 mar 07]. Available from: http://goo.gl/zRrK1E.

Asociación Colombiana de Diabetes (ACD). Ciencia y servicio. Centro Educativo IDF. Prevalencia diabetes en Colombia [Internet]. 2012 [cited 2015 mar 07]. Available from: http://goo.gl/jA7qTt3.

Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature [Internet]. 2001 [cited 2015 mar 07];414(6865):782-7. doi: http://doi.org/csk8xp.

American Diabetes Association. Standards of medical care in diabetes-2015. In: Cefalu, W, editor. Diabetes Care [Internet]. 2015 [cited 2015 mar 07];38(Suppl1):S14-80. doi: http://doi.org/twn.

Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol [Internet]. 2014 [cited 2015 mar 07];76:535-59. doi: http://doi.org/2n5.

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology [Internet]. 2007 [cited 2015 mar 07];132(6):2131-57. doi: http://doi.org/c8rk2h.

Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al.Tests of glycemia in diabetes. Diabetes Care [Internet]. 2004 [cited 2015 mar 07];27(7):1761-73. doi: http://doi.org/b7vg2k.

Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care [Internet]. 2003 [cited 2015 mar 07];26(3):881-5. doi: http://doi.org/fbgp6f.

Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab [Internet]. 2006 [cited 2015 mar 07];91(3):813-9. doi: http://doi.org/fvdh7c.

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia [Internet]. 1996 [cited 2015 mar 07];39(12):1577-83. doi: http://doi.org/bv6cgg.

Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care [Internet]. 2009 [cited 2015 mar 07];32(10):1901-3. doi: http://doi.org/ft22jw.

Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A. Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract [Internet]. 2013 [cited 2015 mar 07];102(2):86-95. doi: http://doi.org/f2n3td.

Creutzfeldt W. The incretin concept today. Diabetologia [Internet]. 1979 [cited 2015 mar 07];16(2):75-85. doi: http://doi.org/cqrb27.

Shapiro ET, Tillil H, Miller MA, Frank BH, Galloway JA, Rubenstein AH, et al. Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes [Internet]. 1987 [cited 2015 mar 07];36(12):1365-71. doi: http://doi.org/2n7.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest [Internet]. 1993 [cited 2015 mar 07];91(1):301-7. doi: http://doi.org/c9drkn.

Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia [Internet]. 2011 [cited 2015 mar 07];54(1):10-8. doi: http://doi.org/c5xhhn.

Nogales-Aguado P, Arrieta-Blanco F. Incretinas: nueva opción terapéutica para la diabetes mellitus tipo 2. JANO [Internet]. 2010 [cited 2015 mar 08];1756(1):62-6. Available from: http://goo.gl/BFrR2a.

Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes [Internet]. 2010 [cited 2015 mar 08];59(7):1765-70. doi: http://doi.org/fj86n4.

Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther [Internet]. 2012 [cited 2015 mar 08];135(3):247-78. doi: http://doi.org/2pf.

Imeryüz N, Yeğen BC, Bozkurt A, Coşkun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol [Internet]. 1997 [cited 2015 mar 08];273(4 Pt1):G920-7. Available from: http://goo.gl/Urq2Vj.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes [Internet]. 2001 [cited 2015 mar 09];50(3):609-13. doi: http://doi.org/d3pbzx.

Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology [Internet]. 2003 [cited 2015 mar 09];144(12):5149-58. doi: http://doi.org/b2c2zk.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes [Internet]. 2013 [cited 2015 mar 09];62(7):2595-604. doi: http://doi.org/2pt.

Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia [Internet]. 1993 [cited 2015 mar 09];36(9):857-62. doi: http://doi.org/fv5mn8.

Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med [Internet]. 1996 [cited 2015 mar 09];37(10):1643-8. PubMed PMID: 8862300.

Chang J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis and its impact on glycemia. Endocrinol Metab Clin North Am [Internet]. 2010 [cited 2015 mar 09];39(4):745-62. doi: http://doi.org/bhvn2c.

Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother [Internet]. 2013 [cited 2015 mar 09];14(9):1171-86. doi: http://doi.org/2pw.

Cheng LK, O'Grady G, Du P, Egbuji JU, Windsor JA, Pullan AJ. Gastrointestinal system. Wiley Interdiscip Rev Syst Biol Med [Internet]. 2010 [cited 2015 mar 09];2(1):65-79. doi: http://doi.org/cv5qsf.

Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol [Internet]. 1991 [cited 2015 mar 09];5(2):371-407. doi: http://doi.org/dm5km7.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol [Internet]. 1997 [cited 2015 mar 09];273(5 Pt1):E981-8. Available from: http://goo.gl/AOdKmh.

Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab [Internet]. 2003 [cited 2015 mar 09];88(6):2719-25. doi: http://doi.org/c6qtrm.

Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab [Internet]. 2004 [cited 2015 mar 09];286(4):E621-5. doi: http://doi.org/bppt5r.

Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care [Internet]. 1999 [cited 2015 mar 09];22(2):339-44. doi: http://doi.org/bm92wh.

Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care [Internet]. 2013 [cited 2015 mar 09];36(5):1396-405. doi: http://doi.org/2p2.

Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med [Internet]. 2010 [cited 2015 mar 09];38(5):1261-9. doi: http://doi.org/bpxtzb.

Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab [Internet]. 2006 [cited 2015 mar 09];91(5):1916-23. doi: http://doi.org/dx7xf4.

Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) [Internet]. 2009 [cited 2015 mar 09];70(3):415-20. doi: http://doi.org/dp6gjd.

Gonlachanvit S, Hsu CW, Boden GH, Knight LC, Maurer AH, Fisher RS, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci [Internet]. 2003 [cited 2015 mar 09];48(3):488-97. doi: http://doi.org/csqsm7.

Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev [Internet]. 2012 [cited 2015 mar 09];33(2):187-215. doi: http://doi.org/2p3.

Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin [Internet]. 2011 [cited 2015 mar 09];27(3):547-58. doi: http://doi.org/dsgn6x.

Yerram P, Whaley-Connell A. Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens [Internet]. 2012 [cited 2015 mar 09];21(5):463-8. doi: http://doi.org/2p4.

Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology [Internet]. 2008 [cited 2015 mar 09];149(2):574-9. doi: http://doi.org/frt6ns.

Sancho V, Trigo MV, Martín-Duce A, González N, Acitores A, Arnés L, et al. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med [Internet]. 2014 [cited 2015 mar 09];17(6):1133-7. doi: http://doi.org/2p6.

Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am [Internet]. 2013 [cited 2015 mar 09];42(4):809-32. doi: http://doi.org/2p7.

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet [Internet]. 2006 [cited 2015 mar 09];368(9548):1696-705. doi: http://doi.org/ffsdxb.

Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract [Internet]. 2012 [cited 2015 mar 09];97(1):27-42. doi: http://doi.org/fxrtd6.

Petersen AB, Knop FK, Christensen M. Lixisenatide for the treatment of type 2 diabetes. Drugs Today (Barc) [Internet]. 2013 [cited 2015 mar 09];49(9):537-53. doi: http://doi.org/2p8.

Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care [Internet]. 2007 [cited 2015 mar 09];30(6):1487-93. doi: http://doi.org/d9wbnh.

Schnabel CA, Wintle M, Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag [Internet]. 2006 [cited 2015 mar 09];2(1):69-77. doi: http://doi.org/d3ghrv.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement executive summary. Endocr Pract [Internet]. 2013 [cited 2015 mar 09];19(3):536-57. doi: http://doi.org/2p9.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care [Internet]. 2012 [cited 2015 mar 09];35(6):1364-79. doi: http://doi.org/2qb.

Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab [Internet]. 2002 [cited 2015 mar 09];87(3):1282-90. doi: http://doi.org/2qc.

Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther [Internet]. 2003 [cited 2015 mar 09];307(2):490-6. doi: http://doi.org/drsqjf.

Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes [Internet]. 2011 [cited 2015 mar 09];60(5):1561-5. doi: http://doi.org/d7pz8z.

Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab [Internet]. 2013 [cited 2015 mar 09];39(6):485-96. doi: http://doi.org/2qd.

Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care [Internet]. 2013 [cited 2015 mar 09];36(10):2945-51. doi: http://doi.org/2qf.

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet [Internet]. 2009 [cited 2015 mar 09];374(9683):39-47. doi: http://doi.org/bkw3wb.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet [Internet]. 2008 [cited 2015 mar 09];372(9645):1240-50. doi: http://doi.org/dfxjr8.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab [Internet]. 2013 [cited 2015 mar 09];15(7):642-9. doi: http://doi.org/2qg.

Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet [Internet]. 2013 [cited 2015 mar 09];381(9861):117-24. doi: http://doi.org/f2fkpd.

Dungan K, DeSantis A. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus [Internet]. 2014 [cited 2015 mar 09]. Available from: http://goo.gl/Lh98fJ.

Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care [Internet]. 2010 [cited 2015 mar 09];33(2):428-33. doi: http://doi.org/fb6cbw.

Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care [Internet]. 2013 [cited 2015 mar 09];36(7):2126-32. doi: http://doi.org/2qk.

Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care [Internet]. 2013 [cited 2015 mar 09];36(7):2118-25. doi: http://doi.org/2qm.

Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ [Internet]. 2013 [cited 2015 mar 09];346:f3750. doi: http://doi.org/2qn.

Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab [Internet]. 2011 [cited 2015 mar 09];96(7):2027-31. doi: http://doi.org/ccm328.

Olansky L. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? Cleve Clin J Med [Internet]. 2010 [cited 2015 mar 09];77(8):503-5. doi: http://doi.org/cs33c6.

Neumiller JJ. Incretin-based therapies. Med Clin North Am [Internet]. 2015 [cited 2015 mar 09];99(1):107-29. doi: http://doi.org/2qp.

Tibaldi JM. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Adv Ther [Internet]. 2014 [cited 2015 mar 09];31(3):289-317. doi: http://doi.org/2qq.

Licencia

Derechos de autor 2015 Revista de la Facultad de Medicina

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.